权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A study on the biological features of age-associated memory impairment (AAMI).

年龄相关记忆障碍（AAMI）生物学特征的研究。

基本信息

批准号：
09671003
负责人：
OHTANI Yoshio
金额：
$ 0.38万
依托单位：
KITASATO UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C).
财政年份：
1997
资助国家：
日本
起止时间：
1997 至 1998
项目状态：
已结题

项目摘要

In order to clarify the biological features of age-associated memory impairment(AAMI) we investigated dilute tropicamide eye drop tests, serum α 1-antichimotrypsine (α 1-ACT) concentrations and apolipoprotein E epsilon 4 allele (ApoE4) frequencies in the normal control elderlys, AAMI subjects, the patients with Alzheimer type dementia(ATD) of early onset type(Alzheimer's disease : AD) and late onset type(senile dementia of Alzheimer's type : SDAT), and those with vascular dementia(VD). Using strict inclusion and exclusion criteria (NINCDS-ADRDA), we recruited 18 patients of AD (63.1±5.8 years old), 26 of SDAT(77.2±4.7 y.o.), 27 of VD(75.0±6.7 y,o.). Regarding AAMI and non-demented controls (C), 24(64.3±12.2 y.o.) and 21(67.6±9.3 y.o.) of persons were enrolled, respectively.Results and conclusion :1) In response to the administration of 0.01% of tropicamide, the value of AAMI group(8.6±6.2%) was nearly equal to that of C group(7.8±5.5%), which tended to be significant to AD-(23.3±19.1%) and SDAT groups(22.0±14.5%)(p<0.1). However, there was no significant differences to either AD or SDAT group.2) Serum α1-ACT values were 278.10±36.3(μg/ml) in AAMI, 259.6±32.7 in C, 303.7±87.8 in AD, 324.2±82.6 in SDAT, 314.7±72.5 in VD group, respectively, so that there was a significant difference only between SDAT and C group (p<0.05).3) The ε4 allele frequency showed the highest value in SDAT group(40.0±40.8%), and the value of AAMI(20.8±29.2%) was beween C(12.5±27.5%) and AD(31.3±40.3%). However, there was no significant difference among each group.Our results suggest that AAMI might not be a distinct clinical entity, but the one which consists of a variety of group such as entirely normal eldelys and a very early stage of Alzheimer Type Dementia.

为探讨年龄相关性记忆损害（AAMI）的生物学特征，对正常老年人、AAMI患者、早发性Alzheimer型痴呆（ATD）患者进行了托吡卡胺滴眼液稀释试验、血清α 1-抗胰蛋白酶（α 1-ACT）浓度和载脂蛋白E β 4等位基因（ApoE 4）频率的研究阿尔茨海默病（Alzheimer’s disease，AD）和晚发型（Alzheimer’s type，SDAT）老年痴呆，以及血管性痴呆（vascular dementia，VD）。采用严格的纳入和排除标准（NINCDS-ADRDA），我们招募了18例AD患者（63.1±5.8岁），26例SDAT患者（77.2±4.7岁），VD组27例（75.0±6.7岁）。关于AAMI和非痴呆对照（C），24（64.3±12.2岁）21例（67.6±9.3岁）结果与结论：（1）在0.01%托吡卡胺作用下，AAMI组（8.6±6.2%）与C组（7.8±5.5%）接近，AD-组（23.3±19.1%）与SDAT组（22.0±14.5%）有显著性差异（p<0.1）。2）血清α1-ACT值AAMI组为278.10±36.3 μg/ml，C组为259.6±32.7 μg/ml，AD组为303.7±87.8 μ g/ml，SDAT组为324.2±82.6 μg/ml，VD组为314.7±72.5 μ g/ml。故仅SDAT组与C组有显著性差异ε4等位基因频率在SDAT组中最高（P<0.05 AAMI组为20.8±29.2%，介于C组（12.5±27.5%）和AD组（31.3±40.3%）之间。提示AAMI可能不是一个独立的临床实体，而是由完全正常的老年人和极早期阿尔茨海默型痴呆（Alzheimer Type Dementia，AD）患者组成的一个综合体。